Insights into signaling from the β2-adrenergic receptor structure

被引:75
作者
Audet, Martin
Bouvier, Michel
机构
[1] Univ Montreal, Dept Biochim, Inst Res Immunol & Canc, Montreal, PQ H3C 3J7, Canada
[2] Univ Montreal, Grp Rech Univ Med, Montreal, PQ H3C 3J7, Canada
关键词
D O I
10.1038/nchembio.97
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
With more than 800 members, the G protein - coupled receptor family constitutes the largest group of membrane proteins involved in signal transduction. Until the end of last year, high-resolution three-dimensional structures were available for only one of them - the light receptor rhodopsin. Recently the structure of the beta 2-adrenergic receptor has been obtained, and it revealed interesting differences with the structure of rhodopsin. Analyses of these differences raise important questions about the binding modes of diffusible ligands in the receptor and allow formulation of testable hypotheses about the structural determinants linking drug binding to specific signaling responses. The three-dimensional structure derived from the beta 2-adrenergic receptor crystal has been used to virtually dock ligands with distinct activities. The different binding modes of these ligands, which correlated with their reported efficacy profiles, suggest that it could be possible to predict the structural determinants of drug signaling efficacies.
引用
收藏
页码:397 / 403
页数:7
相关论文
共 34 条
[1]   β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors [J].
Azzi, M ;
Charest, PG ;
Angers, S ;
Rousseau, G ;
Kohout, T ;
Bouvier, M ;
Piñeyro, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (20) :11406-11411
[2]   Agonist and inverse agonist actions of β-blockers at the human β2-adrenoceptor provide evidence for agonist-directed signaling [J].
Baker, JG ;
Hall, IP ;
Hill, SJ .
MOLECULAR PHARMACOLOGY, 2003, 64 (06) :1357-1369
[3]   THE MAMMALIAN BETA-2-ADRENERGIC RECEPTOR - PURIFICATION AND CHARACTERIZATION [J].
BENOVIC, JL ;
SHORR, RGL ;
CARON, MG ;
LEFKOWITZ, RJ .
BIOCHEMISTRY, 1984, 23 (20) :4510-4518
[4]   GPCR interacting proteins (GIP) [J].
Bockaert, J ;
Fagni, L ;
Dumuis, A ;
Marin, P .
PHARMACOLOGY & THERAPEUTICS, 2004, 103 (03) :203-221
[5]   Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery [J].
Bond, RA ;
IJzerman, AP .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2006, 27 (02) :92-96
[6]   High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor [J].
Cherezov, Vadim ;
Rosenbaum, Daniel M. ;
Hanson, Michael A. ;
Rasmussen, Soren G. F. ;
Thian, Foon Sun ;
Kobilka, Tong Sun ;
Choi, Hee-Jung ;
Kuhn, Peter ;
Weis, William I. ;
Kobilka, Brian K. ;
Stevens, Raymond C. .
SCIENCE, 2007, 318 (5854) :1258-1265
[7]  
CHIDIAC P, 1994, MOL PHARMACOL, V45, P490
[8]  
COSTA T, 1992, MOL PHARMACOL, V41, P549
[9]   Switching of the coupling of the beta(2)-adrenergic receptor to different G proteins by protein kinase A [J].
Daaka, Y ;
Luttrell, LM ;
Lefkowitz, RJ .
NATURE, 1997, 390 (6655) :88-91
[10]   The evasive nature of drug efficacy:: implications for drug discovery [J].
Galandrin, Segolene ;
Oligny-Longpre, Genevieve ;
Bouvier, Michel .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2007, 28 (08) :423-430